KAPPA MYELOMA ANTIGEN CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF

(19)

(11)

EP 3 286 223 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	03.04.2024 Bulletin 2024/14

(45)	Mention of the grant of the patent:
	28.02.2024 Bulletin 2024/09

(21)	Application number: 16784085.9

(22)	Date of filing: 25.04.2016

(51)

International Patent Classification (IPC):

A61P 35/00^(2006.01)
A61K 38/20^(2006.01)
A61K 35/17^(2015.01)
C07K 16/28^(2006.01)
A61K 39/00^(2006.01)
C07K 14/705^(2006.01)

A61P 43/00^(2006.01)
A61K 39/395^(2006.01)
C07K 14/54^(2006.01)
C12N 5/0783^(2010.01)
C07K 14/725^(2006.01)
C07K 16/30^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	C07K 16/30; A61K 38/204; C07K 14/7051; C07K 14/70521; C07K 16/2887; C07K 16/2896; C12N 5/0636; A61K 2039/505; C07K 2317/53; C07K 2317/56; C07K 2319/035; C12N 2510/00; A61K 35/17; C07K 14/5412; C07K 14/5434; A61K 39/395; A61P 35/00; A61P 43/00

(86)	International application number:
	PCT/US2016/029203

(87)	International publication number:
	WO 2016/172703 (27.10.2016 Gazette 2016/43)

(54)	KAPPA MYELOMA ANTIGEN CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF MENSCHLICHE CHIMÄRE ANTIGENREZEPTOREN DES KAPPA-MYELOM-ANTIGENS UND VERWENDUNGEN DAVON RÉCEPTEURS D'ANTIGÈNES CHIMÉRIQUES À ANTIGÈNE DU MYÉLOME KAPPA ET UTILISATIONS ASSOCIÉES

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

23.04.2015 US 201562151968 P
07.05.2015 US 201562158407 P

(43)	Date of publication of application:
	28.02.2018 Bulletin 2018/09

(60)	Divisional application:
	24151551.9

(73)	Proprietor: HaemaLogiX Ltd
	Woolloomooloo NSW 2011 (AU)

(72)	Inventors:
	MICKLETHWAITE, Kenneth Westmead, New South Wales 2145 (AU) DUNN, Rosanne Eveleigh, New South Wales 2015 (AU) GOTTLIEB, David Westmead, New South Wales 2145 (AU) LOGAN, Grant Westmead, New South Wales 2145 (AU)

(74)	Representative: Boult Wade Tennant LLP
	Salisbury Square House 8 Salisbury Square London EC4Y 8AP London EC4Y 8AP (GB)

(56)

References cited: :

WO-A1-03/004056
WO-A1-2010/115238
WO-A1-2014/190273
WO-A2-2004/050836

WO-A1-03/004056
WO-A1-2014/100689
WO-A1-2015/164739
WO-A2-2015/009740

J. VERA ET AL: "T lymphocytes redirected against the ? light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells", BLOOD, vol. 108, no. 12, 1 December 2006 (2006-12-01), pages 3890-3897, XP055232575, US ISSN: 0006-4971, DOI: 10.1182/blood-2006-04-017061
GARFALL AL ET AL: "Immunotherapy with chimeric antigen receptors for multiple myeloma", DISCOVERY MEDICINE: DISCOVERY CLASS OF MEDICINE, RESEARCH TECHNOLOGY, AND T, SOLARIZ, INC, US, vol. 17, no. 91, 1 January 2014 (2014-01-01), pages 37-46, XP009181586, ISSN: 1539-6509
VERA ET AL.: 'T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells.' BLOOD vol. 108, no. 12, 2006, pages 3890 - 7, XP055232575
GARFALL.: 'Immunotherapy with chimeric antigen receptors for multiple myeloma.' DISCOV MED. vol. 17, no. 91, 2014, pages 37 - 46, XP009181586
HOMBACH ET AL.: 'Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD 28-OX40 signalling.' INT J CANCER. vol. 129, no. 12, 2011, pages 2935 - 44, XP055214912
HUSTON ET AL.: 'Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.' PROC NATL ACAD SCI USA. vol. 85, no. 16, 1988, pages 5879 - 83, XP002006553
Andrew T. Hutchinson ET AL: "Free Ig Light Chains Interact with Sphingomyelin and Are Found on the Surface of Myeloma Plasma Cells in an Aggregated Form", The Journal of Immunology, vol. 185, no. 7, 3 September 2010 (2010-09-03), pages 4179-4188, XP55616142, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1001956
PARISA ASVADI ET AL: "MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide", BRITISH JOURNAL OF HAEMATOLOGY, vol. 169, no. 3, 3 February 2015 (2015-02-03), pages 333-343, XP055660579, GB ISSN: 0007-1048, DOI: 10.1111/bjh.13298
ATCC: "HP6053 (ATCC CRL-1758)", , Retrieved from the Internet: URL:https://www.lgcstandards-atcc.org/Prod ucts/All/CRL-1758.aspx?geo_country=nl [retrieved on 2020-01-23]
Adrienne H Long ET AL: "4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors", Nature Medicine, vol. 21, no. 6, 4 May 2015 (2015-05-04), pages 581-590, XP055278553, New York ISSN: 1078-8956, DOI: 10.1038/nm.3838
CARLOS A. RAMOS ET AL: "Clinical responses with T lymphocytes targeting malignancy-associated [kappa] light chains", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 126, no. 7, 1 July 2016 (2016-07-01), pages 2588-2596, XP055627282, GB ISSN: 0021-9738, DOI: 10.1172/JCI86000
SINA FELLERMEIER-KOPF ET AL: "Duokines: a novel class of dual-acting co-stimulatory molecules acting in cis or trans", ONCOIMMUNOLOGY, vol. 7, no. 9, 1 August 2018 (2018-08-01), page e1471442, XP055517180, DOI: 10.1080/2162402X.2018.1471442
BOUX H A ET AL: "A TUMOR-ASSOCIATED ANTIGEN SPECIFIC FOR HUMAN KAPPA MYELOMA CELLS", JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 158, no. 5, 1 November 1983 (1983-11-01), pages 1769-1774, XP001191239, ISSN: 0022-1007, DOI: 10.1084/JEM.158.5.1769


	Remarks:
	The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).